---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-26-000011"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:41:40.105430+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics reports 2025 net loss of $27M; cash $88.9M; Phase 3 enrollment Q3 2026

## Summary
- Full-year 2025 net loss attributable to vTv of $27.0M ($3.20 basic EPS) vs $18.5M ($3.20 basic EPS) in 2024.
- Cash and equivalents $88.9M at Dec 31, 2025, up from $36.7M; plus $20M non-dilutive from Newsoara in Feb 2026.
- Expect to complete enrollment in Phase 3 CATT1 trial for cadisegliatin in T1D in Q3 2026.
- R&D expenses rose to $17.9M in 2025 (2024: $11.5M) driven by higher cadisegliatin clinical spending.
- Amended Newsoara license grants global rights to PDE4 inhibitor HPP737 for $20M upfront plus up to $115M milestones and royalties.

## SEC filing metadata
- accession: 0001641489-26-000011
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000011/0001641489-26-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000011/vtvt-20260310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-26-000011
- JSON: https://secwatch.observer/filing/0001641489-26-000011.json
- Plain text: https://secwatch.observer/filing/0001641489-26-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.